Teva Pharmaceutical Industries (TEVA) said Monday it plans to issue $2 billion equivalent of senior notes through its special purpose finance subsidiaries.
Teva Pharmaceutical Finance Netherlands II intends to offer euro-denominated notes, while Teva Pharmaceutical Finance Netherlands III and Teva Pharmaceutical Finance Netherlands IV aim to offer US dollar-denominated notes.
Separately, the company said it launched cash tender offers for up to $2 billion worth of certain series of notes. The offers are scheduled to expire at 5 pm ET June 17, unless extended or earlier terminated.
Teva said it expects to use the net proceeds from the planned notes issuance, along with cash on hand, to help fund the tender offers, among other things.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。